Structure Therapeutics Reports 16% Weight Loss With Oral GLP-1RA Aleniglipron in Phase 2, Prepares for Phase 3 Obesity Trial and ADA 2026 Data Presentations
Structure Therapeutics Reports Q1 2026 Financial Results and...
Sign in to continue:
Structure Therapeutics Reports Q1 2026 Financial Results and...
Liberty Global Ltd. Announces Major €4.35 Billion Financing ...
European Wax Center, Inc. Shareholder Vote Approves Merger –...
Bar Harbor Bankshares Reports Results of 2026 Annual Meeting...
Hyperscale Data, Inc. Evaluates Strategic Alternatives Amid ...
Rocket Pharmaceuticals Q1 2026 Results & Corporate Update: K...
Concentra Group Holdings Parent, Inc. Q1 2026 Earnings Repor...
Booking Holdings Inc. \$750 Million Senior Notes Offering: K...
Peabody Energy Corporation: Key Shareholder Actions at 2026 ...
Envictus International Holdings Limited: 1H2026 Financial Re...